PF-Atlasניסויים קליניים › NCT04179058

Interstitial Pneumonia With Autoimmune Features: Evaluation of Connective Tissue Disease Incidence During Follow-up

Follow-up · לא צוין

מזהה רישום
NCT04179058
שלב
לא צוין
סטטוס
לא ידוע
תרופה / התערבות
Follow-up
ממן
Central Hospital, Nancy, France
התחלה
2020-03
מספר משתתפים
300
מיקומים
2

על הניסוי

Interstitial lung diseases (ILD) represent a frequent complication of connective tissue diseases (CTDs), especially systemic sclerosis, idiopathic inflammatory myopathies and rheumatoid arthritis. ILD can either occur during CTD course or be the first manifestation of CTDs. Therefore screening patients with ILD for CTD is crucial. In some cases, ILD are associated with clinical and/or serological autoimmune features but not classifiable for CTDs. Evolution of these forms to defined CTDs has never been study. Recently, the European Respiratory Society/American Thoracic Society experts proposed a new term, "interstitial pneumonia with autoimmune features" or IPAF, to describe these patients according to updated classification criteria. Aims of this study were to compare CTD occurence during follow-up between IPAF and non-IPAF patients in a idiopathic interstitial pneumonia cohort and to identify risk factors of CTD progression in IPAF patients at diagnosis.

צפו ב-NCT04179058 ב-ClinicalTrials.gov ←

קישורים קשורים

הבהרה רפואית. דף זה מסכם נתוני ניסוי ציבוריים עבור NCT04179058 למידע בלבד. אין זה ייעוץ רפואי, המלצה או הצעה להשתתף. אמתו פרטים ב-ClinicalTrials.gov ומול רופא מוסמך.